Insider Selling: Vera Therapeutics (NASDAQ:VERA) SVP Sells $130,851.66 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Joseph Young sold 3,117 shares of Vera Therapeutics stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $130,851.66. Following the transaction, the senior vice president owned 64,722 shares in the company, valued at $2,717,029.56. This represents a 4.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Vera Therapeutics Stock Down 3.7%

NASDAQ:VERA opened at $40.79 on Friday. The business’s fifty day moving average price is $46.32 and its 200 day moving average price is $35.49. The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of -8.75 and a beta of 1.16. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Wednesday, February 25th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same quarter in the prior year, the firm earned ($0.72) earnings per share. On average, sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vera Therapeutics

Hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC lifted its position in shares of Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after buying an additional 236 shares during the last quarter. Optimize Financial Inc raised its position in shares of Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after purchasing an additional 256 shares during the period. Virtus Investment Advisers LLC raised its position in shares of Vera Therapeutics by 5.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after purchasing an additional 290 shares during the period. Intech Investment Management LLC lifted its stake in shares of Vera Therapeutics by 2.4% in the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after buying an additional 424 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Vera Therapeutics by 2.0% during the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after buying an additional 550 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Evercore increased their target price on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Pivotal Research set a $73.00 price target on shares of Vera Therapeutics in a research note on Friday, December 5th. JPMorgan Chase & Co. reduced their price objective on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Wedbush boosted their target price on Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, January 21st. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $78.80.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.